The present invention refers to a kalanchoe flammea extract with ethyl acetate (KfAcOEt-COP), the fractions and major compounds thereof, which may be used as cytotoxic or apoptosis inducers against prostate cancer, considering that Docetaxol is a more efficient drug, the KfAcOEt-COP extract (which has fractions and major compounds) shown to have more advantages than Docetaxol. First, a phyto-chemical study was performed where alkaloids, sterols and cardiac glycosides were found. Referring to cytotoxicity, the KfAcOEt-COP effect was evaluated as well as its fractions over the viability of PC3, LNCaP, PrEC and lymphocytes these may exert a doses response effect after 24 h of exposition. Genotoxic studies in vitro and in vivo of KfAcOEt-COP and its fractions were performed, where no toxicity was found. The KfAcOEt-COP extract has evidence of inducing apoptosis after 6 h, the PC3 exposed to the extract showing an overproduction of ROS. The activation of caspases is intrinsically measure d, inducing the fragmentation of the DNA, showing a high level of excision of PARP-1 and inducing cell arrest in the synthesis phase. In an animal model, KfAcOEt-COP is able to inhibit the tumor growth in CaP cells.La presente invención se refiere a un extracto de Kalanchoe flammea con acetato de etilo (KfAcOEt-COP), sus fracciones y sus compuestos mayoritarios, los cuales pueden ser utilizados como citotóxicos o inductores de apoptosis contra cáncer de próstata, y considerando que el Docetaxol es el fármaco más eficaz, el extracto KfAcOEt-COP (el cual tiene fracciones y compuestos mayoritarios), mostró más ventajas que el Docetaxol. Primero, realizamos un estudio fitoquímico donde encontramos alcaloides, esteroles y glucósidos cardiotónicos. En citotoxicidad, evaluamos el efecto de KfAcOEt-COP y sus fracciones sobre la viabilidad de PC3, LNCaP, PrEC y en linfocitos aquí describimos que ellos ejercen un efecto dosis respuesta a las 24 h de exposición. Realizamos estudios genotóxicos in v
